Valuation : Izotropic Corporation

Market Cap 11.99M 10.32M 9.71M 8.87M 16.58M 1.13B 16.64M 115M 44.47M 580M 45.01M 44.03M 1.87B P/E 2027 *
-
P/E 2028 * -
Enterprise Value 11.99M 10.32M 9.71M 8.87M 16.58M 1.13B 16.64M 115M 44.47M 580M 45.01M 44.03M 1.87B EV / Sales 2027 *
2.4x
EV / Sales 2028 * 1.2x
Free-Float
92.14%
Yield 2027 *
-
Yield 2028 * -
1 week-2.08%
1 month-7.84%
3 months-14.55%
6 months+4.44%
Current year-16.07%
1 week 0.22
Extreme 0.215
0.24
1 month 0.21
Extreme 0.21
0.26
Current year 0.19
Extreme 0.19
0.33
1 year 0.19
Extreme 0.19
0.49
3 years 0.04
Extreme 0.035
0.49
5 years 0.04
Extreme 0.035
1.24
10 years 0.04
Extreme 0.035
1.56
Manager TitleAgeSince
Chief Executive Officer 73 01/06/2023
Director of Finance/CFO 75 01/01/2023
Chief Operating Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 73 19/05/2016
Director/Board Member 51 22/05/2017
Director/Board Member 71 01/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/25 Option

Chief Financial Officer

100,000 0.1761%
18/09/25 Option

Chief Financial Officer

100,000 0.1761%
17/09/25 Sell

Chief Financial Officer

100,000 0.1761%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.08%-26.56%-16.07% 11.99M
+3.33%+2.86%-23.88%+1.56% 13.22B
-2.36%-4.13%+10.60%+8.67% 4.23B
+3.96%+3.48%-37.52%-54.42% 1.27B
-1.36%-1.81%-36.41%-40.71% 1.14B
-3.63%-4.16%+15.92%+76.05% 1.07B
-1.80%-0.34% - - 1.03B
-0.50%-2.68%-37.21% - 1.02B
-3.35%-6.37%+25.67%+100.16% 503M
+0.34%+1.01%+67.32% - 300M
Average -0.54%-1.69%-4.67%+10.75% 2.38B
Weighted average by Cap. +1.25%+0.30%-15.29%+3.41%

Financials

2027 *2028 *
Net sales 5M 4.31M 4.05M 3.7M 6.92M 472M 6.94M 47.8M 18.55M 242M 18.77M 18.36M 781M 10M 8.61M 8.1M 7.4M 13.83M 945M 13.88M 95.6M 37.1M 484M 37.55M 36.73M 1.56B
Net income 2.3M 1.98M 1.86M 1.7M 3.18M 217M 3.19M 22M 8.54M 111M 8.64M 8.45M 359M 6.23M 5.36M 5.04M 4.61M 8.62M 588M 8.64M 59.54M 23.1M 301M 23.38M 22.87M 973M
Net Debt - -
Logo Izotropic Corporation
Izotropic Corporation is a Canada-based medical device company. The Company is engaged in commercializing imaging-based products utilizing emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers. Its lzoView computed tomography (CT) Imaging System is intended to produce cross-sectional images of anatomy that can be imaged in the 30 cm aperture by computer reconstruction of x-ray transmission data for non-invasive visualization of tissue. The IzoView is for use in the non-invasive visualization of breast tissue, as an adjunct tool to mammography, by providing x-ray computer reconstructed images as an aid for qualified healthcare providers. The Company has not generated any revenue.
Employees
-
Date Price Change Volume
04/09/26 CA$0.2350 0.00% 33,000
03/09/26 CA$0.2350 +9.30% 15,017
02/09/26 CA$0.2150 0.00% 5,704
01/09/26 CA$0.2150 -8.51% 11,650

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!